Stock Analiz

Tilray Brands, Inc. TLRY

Medicinal Chemicals and Botanical Products · IPO 2018 · data as of November 13, 2026

$2.43Market cap $359M
Open the interactive analysis →

Tilray Brands, Inc. (TLRY) is a healthcare company listed in the US with a market value of about $359M. In the twelve months to August 31, 2026 it had revenue of $963M and net income of -$164M, a net margin of -17.1%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 12% a year, a 5-year average ROIC of -38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 33% below the current price.

About Tilray Brands

Tilray Brands is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2018. Revenue went from $43M in 2018 to $915M in 2026, growth of about 46.5% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 81% over three years (dilution for shareholders). It spends 0% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E34.2
P/FCF—
P/S0.4
P/B0.2
EV/EBITDA24.7
PEG—
Dividend yield0.00%
FCF yield-33.1%
Shareholder yield0.0%
Intrinsic value vs. price−33%

Growth and quality

Revenue growth (1 yr)11.5%
Revenue growth (5 yrs, per year)12.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-123.6%
ROIC (5-yr avg.)-37.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202620252024202320222021202020192018
Revenue$963M$915M$821M$789M$627M$628M$513M$210M$167M$43M
Net income-$164M-$121M-$2.2B-$245M-$1.5B-$477M-$367M-$271M-$321M-$68M
Free cash flow-$119M—-$128M-$60M-$13M-$211M-$84M-$174M-$332M-$96M
EPS (diluted)$-1.41$-1.09$-24.56$-3.30$-23.50$-9.90$-13.60$-21.50$-32.00$-8.20
Net margin-17.1%-13.3%-266.2%-31.1%-231.6%-75.9%-71.6%-128.8%-192.3%-157.0%
ROIC—-2.9%-132.6%-4.3%-36.6%-13.1%-2.8%-45.0%-97.8%-27.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $5.72, 135% above the current price; targets range from $4.00 to $13.00; the consensus rating is “Buy”; expected EPS is $-0.13 for the fiscal year ending May 31, 2027.

Frequently asked questions

Is Tilray Brands stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 33% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Tilray Brands pay a dividend?

Not currently.

Is Tilray Brands a good stock to buy?

We do not give buy or sell advice. Tilray Brands scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.